Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.
The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.
Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.
Marginal Zone Lymphoma
Prior Treatment (Relapsed/Refractory)
A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]
A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-526]
A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase I/II Study of Mogamulizumab and Pembrolizumab Immunotherapy in Recurrent and Persistent Advanced Lymphoma
Erel Joffe
[Protocol 19-018]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]
Follicular Lymphoma
Prior Treatment (Relapsed/Refractory)
A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Lymphoma
Anas Younes
[Protocol 17-073]
A Phase II Study of Atezolizumab Immunotherapy with or without Low-Dose Radiation Therapy for Patients with Recurrent or Persistent Advanced Follicular Lymphoma
M. Lia Palomba
[Protocol 17-360]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase I Study of Pembrolizumab Immunotherapy and TGR-1202 in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]
A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]
Chronic Lymphocytic Lymphoma (CLL)
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
[Protocol 18-427]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase I/II Study of Mogamulizumab and Pembrolizumab Immunotherapy in Recurrent and Persistent Advanced Lymphoma
Erel Joffe
[Protocol 19-018]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]
A Phase I Study of Pembrolizumab Immunotherapy and TGR-1202 in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
Small Lymphocytic Lymphoma (SLL)
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
[Protocol 18-427]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]
A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase I/II Study of Mogamulizumab and Pembrolizumab Immunotherapy in Recurrent and Persistent Advanced Lymphoma
Erel Joffe
[Protocol 19-018]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]
A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]
A Phase I Study of Pembrolizumab Immunotherapy and TGR-1202 in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
Diffuse Large B-Cell Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase III Study of Polatuzumab Vedotin with Standard Immunochemotherapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 18-230]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]
A Phase I Study of REGN3767 and/or REGN2810 Immunotherapy in Patients with Advanced Lymphoma
M. Lia Palomba
[Protocol 17-421]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase III Study of CAR T-Cell Immunotherapy versus Standard Therapy in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma (ZUMA-7)
Miguel-Angel Perales
[Protocol 18-340]
A Phase II Study of CPI-613 for Patients with Recurrent or Persistent Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with High-Risk Genetic Changes
Ariela Noy
[Protocol 18-443]
A Phase I/II Study of Mogamulizumab and Pembrolizumab Immunotherapy in Recurrent and Persistent Advanced Lymphoma
Erel Joffe
[Protocol 19-018]
A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]
A Phase I Study of Pembrolizumab Immunotherapy and TGR-1202 in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
Hodgkin Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-1536]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347]
A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Lymphoma
Anas Younes
[Protocol 17-073]
A Phase II Study of Pembrolizumab Immunotherapy plus Involved Site Radiation Therapy to Treat Early Recurrent or Persistent Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 17-054]
A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 18-160]
A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]
Mantle Cell Lymphoma
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Recurrent or Persistent Mantle Cell Lymphoma
Anita Kumar
[Protocol 17-216]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]
A Phase I/II Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Connie Lee Batlevi
[Protocol 18-450]
A Phase I/II Study of Mogamulizumab and Pembrolizumab Immunotherapy in Recurrent and Persistent Advanced Lymphoma
Erel Joffe
[Protocol 19-018]
A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]
A Phase I Study of Pembrolizumab Immunotherapy and TGR-1202 in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]
T-cell Lymphoma: PTCL, CTCL and Extranodal NK nasal type
Newly Diagnosed/Frontline Studies and Advanced Disease
A Pilot Study of Pembrolizumab Immunotherapy in Patients with Extranodal NK/T-cell Nasal-Type Lymphoma
Alison J. Moskowitz
[Protocol 18-393]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]
A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]
A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042]
A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347]
A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias
Alison J. Moskowitz
[Protocol 18-082]
A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Alison J. Moskowitz
[Protocol 18-147]
A Phase II Study of Duvelisib in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 18-377]
A Phase I/II Study of Mogamulizumab and Pembrolizumab Immunotherapy in Recurrent and Persistent Advanced Lymphoma
Erel Joffe
[Protocol 19-018]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]
A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]
Burkitt Lymphoma
Prior Treatment (Relapsed/Refractory)
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase II Study of CPI-613 for Patients with Recurrent or Persistent Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with High-Risk Genetic Changes
Ariela Noy
[Protocol 18-443]
A Phase I/II Study of Mogamulizumab and Pembrolizumab Immunotherapy in Recurrent and Persistent Advanced Lymphoma
Erel Joffe
[Protocol 19-018]
HIV+ Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
AIDS Malignancy Consortium 101: A Pilot Study to Assess Adding Ibrutinib to Standard R-EPOCH Treatment for AIDS-Related Lymphomas
Ariela Noy
[Protocol 17-543]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
Mark A. Dickson
[Protocol 16-1286]
Waldenstrom’s Macroglobulinemia
Prior Treatment (Relapsed/Refractory)
A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]
A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]
A Phase I/II Study of Mogamulizumab and Pembrolizumab Immunotherapy in Recurrent and Persistent Advanced Lymphoma
Erel Joffe
[Protocol 19-018]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]
A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]
A Phase I Study of Pembrolizumab Immunotherapy and TGR-1202 in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
